HLA-G and neoplasm: The anti-HLA-G scFv may compete with LILRB1 and KIR2D4 receptors on NK cells for HLA-G protein on the tumor membrane, thereby activating NK cell cytotoxicity by downregulating phosphorylated SHP-1 and upregulating phosphorylated Syk/Zap70.